UPMC Hillman Cancer Center

Greg Yothers, PhD

Greg Yothers
Research Associate Professor of Biostatistics
Director, Division of Biostatistics and Science, NRG Oncology Statistics and Data Management Center, Pittsburgh

Contact Information

Contact Information

201 N Craig St
Suite 350, NRG Oncology SDMC
Pittsburgh, PA 15213

Email: gayst3@pitt.edu

Research Keywords

Research Keywords

Colon cancer; rectal cancer; biostatistics; clinical trials

Research Summary

Research Summary

My primary research interest is the design, implementation and analysis of phase II and III clinical trials for cancer research. My work with the NRG Oncology clinical trials cooperative group has included trials evaluating therapies for the treatment of colon and rectal cancer. The focus of my methodological research has been the development of statistical methodologies for identifying a subset of a clinical trial or population where a treatment is effective.

I am the Director of the Division of Biostatistics and Science for the Pittsburgh office of the NRG Oncology Statistics and Data Management Center; this leadership role involves maintaining effective operations to support numerous clinical trials in a research group comprising 200 employees. I have sole responsibility for the program of research in colorectal cancer.

Selected Publications

Selected Publications

  • O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from national surgical adjuvant breast and bowel project trial R-04. J Clin Oncol. 2014 Jun 20;32(18):1927-34. PubMed Link
    Shared Resources Used: BF
  • Russell MM, Ganz PA, Lopa S, Yothers G, Ko CY, Arora A, Atkins JN, Bahary N, Soori GS, Robertson JM, Eakle J, Marchello BT, Wozniak TF, Beart RW Jr, Wolmark N. Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04. Annals of Surgery. 2014 Mar 25. PubMed Link
    Shared Resources Used: BF
  • Yothers G, O'Connell MJ, Lee M, Lopatin M, Clark-Langone K, Millward C, Paik S, Sharif S, Shak S, Wolmark N. Validation of the 12-gene colon cancer Recurrence Score in NSABP C-07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5-FU/LV and 5-FU/LV+oxaliplatin. J Clin Oncol. 2013 Dec 20;31(36):4512-9. PubMed Link
    Shared Resources Used: BF
  • McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, O'Connell M, Twelves CJ, Saltz LB, Haller DG, Sargent DJ. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2013 Jul 10;31(20):2600-6. PubMed Link
  • Pogue-Geile K, Yothers G, Taniyama Y, Tanaka N, Gavin P, Colangelo L, Blackmon N, Lipchik C, Kim SR, Sharif S, Allegra C, Petrelli N, O'Connell MJ, Wolmark N, Paik S. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst. 2013 Jul 3;105(13):989-92. PubMed Link
    Shared Resources Used: BF
  • Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, Wolmark N. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013 Jan 20;31(3):359-64. PubMed Link
    Shared Resources Used: BF
  • Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, Cecchini RS, Kopec JA, Wolmark N. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer. 2012 Nov 15;118(22):5614-22. PubMed Link
  • Sill MW, Rubinstein L, Litwin S, Yothers G. A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials. Clin Trials. 2012 Aug;9(4):385-95. PubMed Link
    Shared Resources Used: BF
  • Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW, ACCENT Collaborative Group. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011 Oct 19;103(20):1498-506. PubMed Link
    Shared Resources Used: BF
  • Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011 Oct 1;29(28):3768-74. PubMed Link
    Shared Resources Used: BF

See all pubs (Pubmed)

Collaborations

Collaborations

Current External Collaborators

Carmen Allegra, MD
Professor of Medicine
University of Florida, Shands Cancer Center

Patricia Ganz, MD
Director of Cancer Prevention and Control Research
UCLA, Jonsson Comprehensive Cancer Center

Nicholas Petrelli, MD
Medical Director
Helen F. Graham Cancer Center

Daniel Sargent, PhD
Professor of Biostatistics and Oncology
Mayo Clinic

Shared Resource Usage

Shared Resource Usage

  • Biostatistics Facility

Affiliated Graduate Programs

Department Website









Last modified: 6/17/14